Skip to main content

Analysts’ Top Healthcare Picks: Context Therapeutics (CNTX), Connect Biopharma Holdings (CNTB)

Tipranks - Tipranks - Thu Jan 22, 11:12AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Context Therapeutics (CNTX – Research Report), Connect Biopharma Holdings (CNTB – Research Report) and HeartBeam (BEAT – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Context Therapeutics (CNTX)

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Context Therapeutics today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.54.

According to TipRanks.com, Bodnar is a 4-star analyst with an average return of 12.4% and a 34.0% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Acrivon Therapeutics, Inc., and Olema Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Context Therapeutics with a $5.25 average price target, implying a 236.5% upside from current levels. In a report issued on January 15, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $1.50 price target.

See today’s best-performing stocks on TipRanks >>

Connect Biopharma Holdings (CNTB)

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Connect Biopharma Holdings today and set a price target of $7.00. The company’s shares closed last Wednesday at $2.48, close to its 52-week high of $2.66.

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 1.9% and a 41.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Milestone Pharmaceuticals. ;'>

Currently, the analyst consensus on Connect Biopharma Holdings is a Strong Buy with an average price target of $8.67, implying a 268.9% upside from current levels. In a report issued on January 13, Lake Street also maintained a Buy rating on the stock with a $9.00 price target.

HeartBeam (BEAT)

In a report released today, Yi Chen from H.C. Wainwright maintained a Buy rating on HeartBeam, with a price target of $5.50. The company’s shares closed last Wednesday at $1.90, close to its 52-week low of $1.70.

According to TipRanks.com, Chen is a 3-star analyst with an average return of 2.8% and a 44.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Virax Biolabs Group Ltd. Class A, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on HeartBeam is a Strong Buy with an average price target of $5.83.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).